Common Cold News and Research

RSS

Combination treatment provides effective one-two punch against prostate cancer

Results from a long-term clinical trial conducted by cancer researchers at Houston Methodist Hospital show that combining radiation treatment with "suicide gene therapy," a technique in which prostate cancer cells are genetically modified so they signal a patient's immune system to attack them, provides a safe and effective one-two punch against the disease.

12 Dec 2015

SLU infectious diseases experts answer flu season questions

A cure for the common cold isn't in the crystal ball of an infectious diseases researcher and physician at Saint Louis University's Center for Vaccine Development.

23 Nov 2015

Simple self-rating of health accurately predicts susceptibility to common cold

New research from Carnegie Mellon University psychologists shows that a simple self-rating of health accurately predicts susceptibility to the common cold in healthy adults aged 18-55 years. Published in Psychosomatic Medicine, the study - led by CMU's Sheldon Cohen - indicates that low self-rated-health is associated with poorer immune system competence.

10 Nov 2015

Viralytics enters into clinical trial collaboration agreement with MSD

Viralytics Limited announced today that it has entered into a clinical trial collaboration agreement through subsidiaries of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. (known as MSD outside the United States and Canada) to evaluate the combination of Viralytics' investigational cancer immunotherapy CAVATAK, with MSD's KEYTRUDA, an anti-PD-1 (programmed death receptor-1) therapy.

6 Nov 2015

Camels in Kenya infected by MERS virus, new study finds

A new study has found that nearly half of camels in parts of Kenya have been infected by the virus that causes Middle East Respiratory Syndrome (MERS) and calls for further research into the role they might play in the transmission of this emerging disease to humans.

19 Oct 2015

Outbreak of Bordetella parapertussis occurred in Southeastern Minnesota in 2014: Study

Study reports that an outbreak of Bordetella parapertussis occurred in 2014 in Southeastern Minnesota, in the months of October through December. This research is presented at ASM's 55th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC/ICC).

22 Sep 2015

Vernalis Therapeutics announces availability of codeine-based cough and cold syrup in the U.S.

Vernalis Therapeutics Inc., a subsidiary of Vernalis plc, today announced that Tuzistra XR (codeine polistirex and chlorpheniramine polistirex), extended-release oral suspension, CIII (DEA Schedule III) is now available to adult patients and physicians in the United States.

8 Sep 2015

Antibiotic resistance awareness: an interview with Professor Colin Garner

The threat of antibiotic resistance is very real. It is estimated that 700,000 people die each from resistant infections. In Europe the figure is 25,000 deaths and a similar number in the USA.

7 Sep 2015

Penn researchers identify viral products that trigger immune response against RSV infection

Almost all human beings are exposed to the respiratory syncytial virus, or RSV, before their second birthdays. For most, the symptoms mimic those of the common cold: runny nose, coughing, sneezing, fever.

4 Sep 2015

Sleep loss increases chance of catching a cold

A new study led by a UC San Francisco sleep researcher supports what parents have been saying for centuries: to avoid getting sick, be sure to get enough sleep.

1 Sep 2015

Children increase parents’ risk for viral infection

The BIG LoVE (Utah Better Identification of Germs-Longitudinal Viral Epidemiology) study, led by scientists at the University of Utah School of Medicine, finds that each bundle of joy puts the entire household at increased risk for infection with viruses that cause colds, flu, and other respiratory illnesses.

5 Aug 2015

FDA approves Praluent (alirocumab) Injection for treatment of patients with high LDL cholesterol

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration approved Praluent (alirocumab) Injection, the first FDA-approved treatment in a new class of drugs known as PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors.

25 Jul 2015

Researchers develop diagnostic test to detect enterovirus D68

Researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year. The outbreak caused infections at an unprecedented rate, with over 1,000 confirmed cases and 14 reported deaths nationwide, according to the Centers for Disease Control and Prevention.

23 Jul 2015

Canadian researchers launch world's first viral therapy clinical trial to attack and kill cancer cells

Canadian researchers have launched the world's first clinical trial of a novel investigational therapy that uses a combination of two viruses to attack and kill cancer cells, and stimulate an anti-cancer immune response. Previous research by this team and others worldwide suggests that this approach could be very powerful, and could have fewer side effects than conventional chemotherapy and radiation, although it will take years to rigorously test through this trial and others.

13 Jul 2015

Bidding for Health charity auction to raise funds in support of Immunodeficiency Canada

Bidding for Health charity auction will raise much needed funds in support of a Canadian national registered charity Immunodeficiency Canada. 100% of proceeds raised will be used towards its programs and services. There is a wide range of exciting items to bid on with new items added throughout the month, so check back often. Something for all ages.

3 Jul 2015

Atopix raises additional development capital to investigate OC459 for treatment of asthma

Atopix Therapeutics Limited, a UK biopharmaceutical company developing a novel class of medicines to treat atopic dermatitis and severe asthma, today announced that it has raised additional development capital to advance its lead product OC459 for the treatment of asthma.

17 Jun 2015

Intermountain Healthcare participates in antibiotic stewardship forum at the White House

Intermountain Healthcare is one of 150 organizations in the nation that was invited to the White House to help develop national policy to address the growing problem of the overuse of antibiotics.

3 Jun 2015

Talimogene laherparepvec treatment shows durable clinical responses in advanced-stage melanoma patients

Research led by Howard L. Kaufman, MD, FACS, associate director for clinical science and chief surgical officer at Rutgers Cancer Institute of New Jersey and colleagues, shows advanced-stage melanoma patients have significant improvement in durable response rate and a trend toward improved survival when treated with a genetically-modified form of a herpes virus, whose native form causes the common cold sore.

2 Jun 2015

International study reveals that cold weather kills far more people than hot weather

The study analysed over 74 million (74225200) deaths between 1985 and 2012 in 13 countries with a wide range of climates, from cold to subtropical...

21 May 2015

DNAtrix signs agreement to utilize Alcyone's MEMS platform for direct drug delivery into glioblastoma

Alcyone Lifesciences, Inc., a leader in neural intervention systems for neurological conditions and targeted drug delivery, and DNAtrix Inc., a privately held biotechnology company and a leader in oncolytic virus therapy, have entered into an exclusive clinical collaboration. Under the agreement, DNAtrix will utilize Alcyone's MEMS Cannula (AMC) targeted delivery platform for the intratumoral delivery of DNX-2401, an oncolytic adenovirus and DNAtrix's lead product for the treatment of the most aggressive form of brain cancer, glioblastoma (GBM).

19 May 2015